Anti-PARP2 antibody [EPR24240-29],Abcam,AB271080

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

WB

Platform ID

BAB352863631

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-PARP2 antibody [EPR24240-29]
Cat. No.AB271080
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB
ClonalityMonoclonal
Clone NumberEPR24240-29
Concentration0.556 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair (PubMed : 10364231, PubMed : 25043379, PubMed : 27471034, PubMed : 30104678, PubMed : 32028527, PubMed : 32939087, PubMed : 34108479, PubMed : 34486521, PubMed : 34874266). Mediates glutamate, aspartate or serine ADP-ribosylation of proteins : the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units (PubMed : 25043379, PubMed : 30104678, PubMed : 30321391). Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage (PubMed : 32939087). Mediates glutamate and aspartate ADP-ribosylation of target proteins in absence of HPF1 (PubMed : 25043379). Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 conferring serine specificity by completing the PARP2 active site (PubMed : 28190768, PubMed : 32028527, PubMed : 34108479, PubMed : 34486521, PubMed : 34874266). PARP2 initiates the repair of double-strand DNA breaks : recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones, thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks (PubMed : 10364231, PubMed : 32939087, PubMed : 34108479). HPF1 initiates serine ADP-ribosylation but restricts the polymerase activity of PARP2 in order to limit the length of poly-ADP-ribose chains (PubMed : 34732825, PubMed : 34795260). Specifically mediates formation of branched poly-ADP-ribosylation (PubMed : 30104678). Branched poly-ADP-ribose chains are specifically recognized by some factors, such as APLF (PubMed : 30104678). In addition to proteins, also able to ADP-ribosylate DNA : preferentially acts on 5'-terminal phosphates at DNA strand breaks termini in nicked duplex (PubMed : 27471034, PubMed : 29361132). See full target information PARP2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.